Attached files
| file | filename |
|---|---|
| EX-10.20 - EXHIBIT 10.20 - Travere Therapeutics, Inc. | ex1020-1231201710k.htm |
| EX-32.2 - EXHIBIT 32.2 - Travere Therapeutics, Inc. | ex322-1231201710k.htm |
| EX-32.1 - EXHIBIT 32.1 - Travere Therapeutics, Inc. | ex321-1231201710k.htm |
| EX-31.2 - EXHIBIT 31.2 - Travere Therapeutics, Inc. | ex312-1231201710k.htm |
| EX-31.1 - EXHIBIT 31.1 - Travere Therapeutics, Inc. | ex311-1231201710k.htm |
| EX-21.1 - EXHIBIT 21.1 - Travere Therapeutics, Inc. | ex211-1231201710k.htm |
| 10-K - 10-K - Travere Therapeutics, Inc. | rtrx-20171231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Retrophin, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-202861, 333-198648 and 333-198648) and Form S-8 (Nos. 333-218582, 333-213599, 333-206510 and 333-200224) of Retrophin, Inc. of our reports dated February 27, 2018, relating to the consolidated financial statements and the effectiveness of Retrophin, Inc.’s internal control over financial reporting, which appear in this Form 10-K.
/s/ BDO USA, LLP
New York, New York
February 27, 2018